Patented Immunotherapy Candidate
Learn More
Board of Directors Expanded
Learn More
Discovery to Science-Led Public Company
Learn More
CEO Dwain Irvin, PhD, MPH, Attended Recent BioTech Conference
Learn More
Previous
Next
Patented Immunotherapy Candidate
Learn More
Board of Directors Expanded
Learn More
The Journey from Discovery to IPO
Learn More
CEO Dwain Irvin, PhD, MPH, Attended Recent BioTech Conference
Learn More
Previous
Next
Patented Immunotherapy Candidate
Board of Directors Expanded
The Journey from Discovery to IPO
CEO Dwain Irvin, PhD, MPH, Attended Recent BioTech Conference
Previous
Next

Our patented approach, TLR-AD1 seeks to bolster the body’s immune system through cellular training; strengthening the body’s defense against cancer.

With TLR-AD1, we will provide Novel Access to the Global market.

Join Us